Comprehensive Study Guide: First-Generation Antipsychotics and Dopamine Antagonism

Overview of Dopamine 2 Receptor Antagonists

Terminology and Nomenclature Shifting * Traditional terminology refers to these medications as "antipsychotics." * Modern medicine is moving away from the term "antipsychotics" because these agents serve multiple clinical purposes beyond treating psychosis. * There are $D_2$ (Dopamine 2) antagonists that are not used as antipsychotics (e.g., for gastrointestinal issues or other non-psychiatric conditions). * Conversely, "antipsychotic" medications are frequently used to treat non-psychotic conditions such as Bipolar Disorder or Major Depressive Disorder (MDD). * The preferred classification is shifting toward mechanism of action (MOA) rather than clinical end goals.
Core Categories of Antipsychotics * Typical Antipsychotics: Also known as Neuroleptics, Conventional Antipsychotics, or First-Generation Antipsychotics (FGAs). These are primarily defined as Dopamine Receptor Antagonists, specifically targetting the $D_2$ receptor. * Atypical Antipsychotics: Also known as Second-Generation Antipsychotics (SGAs). These work through actions on both Serotonin and Dopamine, typically in an antagonistic fashion.

The Dopamine Hypothesis and Mechanism of Action

Foundational Approach * For decades, the treatment of psychosis has centered on the dopamine hypothesis. * Psychosis and Schizophrenia are understood to be caused by excessive dopamine activity in the mesolimbic or mesostriatal pathways of the brain.
Mechanism of First-Generation Agents * Classically, medications treat psychosis by blocking dopamine through $D_2$ antagonism. * While newer agents may act as partial agonists or target systems other than $D_2$ , the hallmark of a conventional antipsychotic remains its $D_2$ antagonist properties.
Therapeutic Thresholds * To achieve an effective antipsychotic action, a specific threshold of dopamine blockade must be reached. * The Antipsychotic Window: Clinical research indicates that approximately $60\% \text{ to } 80\%$ of the $D_2$ receptors must be blocked to see a reduction in psychotic symptoms. * Efficacy vs. Toxicity: This is a narrow window. If blockade is below $60\%$ , the drug is ineffective as an antipsychotic. If blockade exceeds $80\%$ , the side effect burden (extrapyramidal symptoms) outweighs the therapeutic benefits.

Receptor Affinities and Multi-Receptor Activity

Non-Selective Blockade * Few medications are pure $D_2$ antagonists. Most first-generation agents are "equal opportunity blockers," meaning they affect various receptor sites. * Common off-target receptors include: * Muscarinic (M1): Blockade leads to anticholinergic side effects. * Histamine (H1): Blockade leads to sedation and weight gain. * Alpha (\alpha): Blockade leads to orthostatic hypotension.
Dopamine Pathway Specificity Problems * Mesolimbic/Mesostriatal: Blockade here reduces positive symptoms but can also decrease reward/pleasure responses, potentially worsening negative symptoms. * Mesocortical: If dopamine is already low here in Schizophrenia, further blockade can create secondary negative symptoms. * Nigrostriatal: Blockade results in Extrapyramidal Side Effects (EPS), such as pseudo-parkinsonism, akathisia, and long-term Tardive Dyskinesia (TD). * Tuberoinfundibular: Blockade here causes prolactin elevation, leading to associated side effects (e.g., galactorrhea, gynecomastia).

Potency vs. Efficacy in First-Generation Antipsychotics

The Potency Distinction * Potency is NOT Efficacy: A more potent drug is not more effective at treating symptoms; a low-potency drug is not less effective. * Definition of Potency: Potency refers specifically to the affinity a drug has for binding to a receptor (in this case, the $D_2$ receptor).
Low-Potency Antipsychotics * Affinity: These have a higher affinity for Histamine and Muscarinic receptors relative to the $D_2$ receptor. * Dosing: Require higher numerical doses to achieve the $60\% \text{ to } 80\%$ $D_2$ blockade. * Side Effects: High likelihood of sedation, weight gain, and anticholinergic effects, but a lower risk of EPS.
High-Potency Antipsychotics * Affinity: These have a very high affinity for the $D_2$ receptor and a much lower affinity for Histamine and Muscarinic receptors. * Side Effects: Low likelihood of sedation or anticholinergic effects, but a much higher risk of Extrapyramidal Side Effects.

Neuroleptic Malignant Syndrome (NMS) vs. Serotonin Syndrome

Psychiatry faces two rare but major medical emergencies that present similarly. Distinguishing them as a provider is critical.

Neuroleptic Malignant Syndrome (NMS) * Causative Agent: Meds that block dopamine (all antipsychotics carry this class effect risk). * Onset: Typically develops within the first 7 days of starting a drug or increasing the dose ( $2/3$ of cases occur in this window). * Physical Findings: Characterized by Lead Pipe Muscle Rigidity, slower reflexes (hyporeflexia), and Parkinsonian symptoms. * Autonomic Instability: High heart rate, blood pressure, and temperature.
Serotonin Syndrome (SS) * Causative Agent: Meds that increase serotonin. * Onset: Typically occurs within 24 hours. * Physical Findings: Characterized by a hyperactive state, including clonus, increased reflexes (hyperreflexia), and tremors.

NMS Clinical Management

Nature of the Reaction: NMS is considered an idiosyncratic reaction or "freak accident," rather than simple toxicity or overdose.
Intervention Steps: 1. Medical Emergency: Move the patient to a hospital; NMS cannot be managed in an outpatient setting. 2. Stop Offending Agent: Immediately discontinue all dopamine blockers. 3. Supportive Care: Temperature reduction, correction of dehydration, and electrolyte balancing. Mechanical ventilation may be required. 4. Pharmacological Support: * IV Benzodiazepines (e.g., Ativan, Valium). * IV Dantrolene: A skeletal muscle relaxant used for extreme hyperthermia or non-response to other care. * Dopamine Agonists: Bromocriptine or Amantadine (acts to reverse dopamine blockade). 5. Refractory Cases: Electroconvulsive Therapy (ECT) is an option.
Resuming Treatment After NMS * NMS is not a contraindication to future antipsychotic use once resolved. * Estimated recurrence rate: $2\% \text{ to } 30\%$ . * Guidelines for Restarting: * Wait until NMS has completely resolved. * Start at the lowest possible dose and monitor closely. * Prefer Second-Generation over First-Generation. * If using First-Generation, prefer low-potency over high-potency. * Avoid Lithium: It is a potential (though controversial) risk factor for NMS. * Avoid dehydration.

First-Generation Prototype Drugs

Chlorpromazine (Prototype Low-Potency) * The first conventional antipsychotic discovered. * Characteristics: A "dirty drug" that hits many receptors; formerly brand-named "Largactyl" due to its "large range of actions." * Specific Side Effects: * Seizure Threshold: The only conventional antipsychotic associated with significantly lowering the seizure threshold. * Photosensitivity (Pheno-Photo): It is a phenothiazine. High doses/prolonged use can cause a blue-gray pigment change in sun-exposed skin and corneal/lens deposits (generally benign and reversible).
Haloperidol/Haldol (Prototype High-Potency) * Commonly prescribed due to lack of anticholinergic activity, making it a favorite for delirium. * Administration: Oral, IM (short-acting and long-acting depot), and IV. * QTc Risk: IV administration carries a significantly higher risk for QTc interval prolongation; oral and IM risks are minimal. * Side Effects: High incidence of EPS and Tardive Dyskinesia due to high $D_2$ affinity. Low incidence of sedation and weight gain.

Antipsychotic Overdose Management

Not NMS: Antipsychotic overdose is separate from the idiosyncratic NMS reaction.
Treatment: Management is purely supportive care.
Antidote: There is no specific pharmacological antidote for antipsychotic overdose.
Monitoring: No specific labs; care focuses on managing symptoms as they arise in an overdose scenario.